Vildagliptin (Galvus)

DRUG2 trials

Sponsors

University Hospital, Strasbourg, France, Fundación para la Investigación del Hospital Clínico de Valencia

Conditions

Diabetes Mellitus Type 2Haemodialyzed, Type 2 Diabetes

Phase 4

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

CompletedNCT02176681

University Hospital, Strasbourg, FranceHaemodialyzed, Type 2 Diabetes

Start: 2014-06-01End: 2017-10-01Updated: 2026-03-16

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Active, not recruitingNCT06851962

Fundación para la Investigación del Hospital Clínico de ValenciaDiabetes Mellitus Type 2

Start: 2025-05-26End: 2026-06-30Target: 504Updated: 2026-02-23